



JCO2 Rec'd PCT/PTO 29 APR 2002

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0180

Inventors: Macina, Roberto A.

Serial No.: 09/806,302 ✓

Filing Date: 29 March 2001

Examiner: Unknown

Group Art Unit: Unknown

Title: A Novel Method of Diagnosing,
Monitoring, Staging, and Treating
Gynecologic Cancers

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: April 22, 2002

Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) A copy of the of the PCT Search Report for PCT/US99/22753 which corresponds to the subject US application 09/806,302 is included.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449

(modified) [redacted] are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.


(XX) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO 99/53051 A2 (pages 1-152, figures 1-10, sequence listing pages 1, 405, 654). Full text of abbreviated reference is available if requested.

(XX) Reference WO 99/54461 A2 is in a foreign language. Therefore, a Geneseq Patent search report for the original corresponding German National Application, DE 19817948-A1, is attached to demonstrate relevance.

() All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts
Registration No. 36,581

Date: April 22, 2002

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Serial Number

0302

Filing Date

29 March 2001

Applicant

Roberto A. Macina

Group Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

DEX-0180

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date MM-DD-YYYY
	AA	US 6,066,724	05/23/2000	Ni et al.			03/21/1997
	AB	US 6,174,992	01/16/2001	Ni et al.			03/08/1999
	AC	US 6,228,596	05/08/2001	Macina et al.			03/05/1998

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation/ Comments
	AC	WO 96/38463 A1	12/05/1996	Watson et al.			
	AD	WO 97/34997 A1	09/25/1997	Ni et al.			
	AE	WO 98/35229 A1	08/13/1998	Morris et al.			
	AF	WO 99/19487 A1	04/22/1999	Hillman et al.			
	AG	WO 99/53051 A2	10/21/1999	Dumas Milne Edwards et al.			Abbreviated
	AH	WO 99/54461 A2	10/28/1999	Specht et al.			No Trans.
	AI	WO 00/20044 A1	04/13/2000	Macina, Roberto A.			
	AJ	WO 00/20447 A2	04/13/2000	Shimkets, Richard A.			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Author, title of the article, title of the item, date, volume-issue number, page(s).	Translation/ Comments
	AK	Aoki et al., Isolation of human uteroglobin from blood filtrate. Mol. Hum. Repro. 1996; Vol. 2(7):489-497.	
	AL	Becker et al., Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics. 1998; Vol. 54:70-78.	
	AM	Chilton et al., Zinc finger proteins RUSH in where others fear to tread. Biol. Of Reprod. 1998; Vol. 58:285-294.	
	AN	Claessens et al., Sequence-specific binding of androgen-receptor complexes to prostatic binding protein genes. Mol. Cell. Endo. 1990; Vol. 74:203-212.	
	AO	Claessens et al., Intronic androgen response elements of prostatic binding protein genes. BBRC. 15 Mar 1993; Vol. 191(2):688-694.	
	AP	Claessens et al., Functional androgen response elements in the genes coding for prostatic binding protein. Annals NY Acad. Sci. 1993; Vol. 684:199-201.	
	AQ	Colpitts et al., Mammaglobin is found in breast tissue as a complex with BU101. Biochemistry. 2001; Vol. 40:11048-11059.	
	AR	Gow, Alexander, Redefining the lipophilin family of proteolipid proteins. J. Neurosci. Res. 1997; Vol. 50:659-664.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Serial Number 1,302

Filing Date 29 March 2001

Applicant Roberto A. Macina

Group Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number DEX-0180

AS	Koshiyama et al., Expression of pS2 protein in Endometrial carcinomas: correlation with clinicopathological features and sex steroid receptor status. Int. J. Cancer. 1997; Vol. 74:237-244.	
AT	Lehrer et al., Lipophilin, a novel heterodimeric protein of human tears. FEBS Letters. 1998; Vol. 432:163-167.	
AU	Lehrer et al., Secretory lipophilins: A tale of two species. Annals NY Acad. Sci. 2000; Vol. 923:59-67.	
AV	Maroulakou et al., Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. PNAC. Nov 1994; Vol. 91:11236-11240.	
AW	Ni et al., All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Annals NY Acad. Sci. 2000; Vol. 923:25-42.	
AX	Sasano et al., Adrenal 4-binding protein in common epithelial and metastatic tumors of the ovary. Human Pathology. Jun 1996; Vol. 27(6):595-598.	
AY	Scholz et al., Hormone-induced recruitment of Sp1 mediates estrogen activation of rabbit uteroglobin gene in Endometrial epithelium. JBC. 20 Feb 1998; Vol. 273(8):4360-4366.	
AZ	Schmitt et al., Time varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status primary breast cancer. British J. Cancer. 1997; Vol. 76(3):306-311.	
BA	Shao et al., Prostatein C ₃ -mRNA: a sensitive marker of androgen-responsiveness in prostate explant cultures. The Prostate. 1990; Vol. 17:41-55.	
BB	Shibata et al., Altered expression of transforming growth factor β s during urethral and bulbourethral gland tumor progression in transgenic mice carrying that androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen. Carcinogenesis. 1998; Vol. 19(1):195-205.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.